Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder

Progress in Neuro-psychopharmacology & Biological Psychiatry
Vala RezaeiShahin Akhondzadeh

Abstract

Autism is a complex neurodevelopmental disorder that forms part of a spectrum of related disorders referred to as Autism Spectrum Disorders. The present study assessed the effects of topiramate plus risperidone in the treatment of autistic disorder. Forty children between the ages of 4 and 12 years with a DSM IV clinical diagnosis of autism who were outpatients from a specialty clinic for children were recruited. The children presented with a chief complaint of severely disruptive symptoms related to autistic disorder. Patients were randomly allocated to topiramate+risperidone (Group A) or placebo+risperidone (Group B) for an 8-week, double-blind, placebo-controlled study. The dose of risperidone was titrated up to 2 mg/day for children between 10 and 40 kg and 3 mg/day for children weighting above 40 kg. The dose of topiramate was titrated up to 200 mg/day depending on weight (100 mg/day for <30 kg and 200 mg/day for >30 kg). Patients were assessed at baseline and after 2, 4, 6 and 8 weeks after starting medication. Measure of outcome was the Aberrant Behavior Checklist-Community (ABC-C) Rating Scale. Difference between the two protocols was significant as the group that received topiramate had a greater reduction in ABC-C sub...Continue Reading

References

Sep 14, 2004·Mental Retardation and Developmental Disabilities Research Reviews·Roberto Tuchman
Jun 25, 2005·Mental Retardation and Developmental Disabilities Research Reviews·Susan E Levy, Susan L Hyman
Jun 27, 2006·Brain & Development·Luigi Mazzone, Liliana Ruta
Jul 21, 2006·Journal of Clinical Psychopharmacology·Evdokia AnagnostouEric Hollander
May 16, 2007·Journal of Clinical Psychopharmacology·Helmut Niederhofer
Aug 10, 2007·Expert Opinion on Pharmacotherapy·Scott M Myers
Oct 12, 2007·Child Psychiatry and Human Development·Shahin AkhondzadehHossein-Ali Ghelichnia
Apr 4, 2008·The Journal of Headache and Pain·Diana Ferraro, Girolamo Di Trapani
Apr 17, 2008·Harvard Review of Psychiatry·Thomas J LeskovecRobert L Findling
Feb 24, 2009·Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners·Lis WestSusan Brunssen
Sep 24, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Shahin AkhondzadehSaeedeh Forghani

❮ Previous
Next ❯

Citations

Mar 7, 2012·Child Psychiatry and Human Development·Elmira HasanzadehShahin Akhondzadeh
Sep 13, 2011·American Journal on Intellectual and Developmental Disabilities·Deborah K AndersonCatherine Lord
Oct 1, 2013·Journal of Autism and Developmental Disorders·Tomoya HirotaTaro Kishi
Feb 4, 2014·Current Psychiatry Reports·Danielle A Baribeau, Evdokia Anagnostou
May 4, 2012·Expert Opinion on Pharmacotherapy·Carolyn A Doyle, Christopher J McDougle
May 1, 2012·Brain & Development·Arianna BenvenutoPaolo Curatolo
May 10, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Alessandro ZuddasTatiana Usala
Apr 29, 2015·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Chris Oliver, Caroline Richards
Nov 12, 2014·Expert Opinion on Drug Metabolism & Toxicology·Mariken DinnissenPieter J Hoekstra
Feb 5, 2013·Journal of Pediatric Urology·Nicol Corbin BushKhashayar Sakhaee
Mar 10, 2015·Journal of Child and Adolescent Psychopharmacology·Brittany CrowleyChristopher J McDougle
Sep 25, 2012·The International Journal of Neuropsychopharmacology·Ali GhaleihaShahin Akhondzadeh
Apr 30, 2016·Journal of Child and Adolescent Psychopharmacology·Ali GhaleihaShahin Akhondzadeh
Oct 30, 2013·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Helena BrentaniJames T McCracken
Jan 24, 2014·Journal of Psychopharmacology·Jessica MemarziaGiovanni Giaroli
Dec 19, 2015·International Journal of Psychiatry in Medicine·Michael ShapiroMathew Nguyen
Jun 16, 2018·Acta Psychiatrica Scandinavica·S H AmeisC U Correll
Apr 24, 2013·Journal of Child and Adolescent Psychopharmacology·Kathryn Yuill, Carlo Carandang
Mar 6, 2010·Journal of Autism and Developmental Disorders·Kathleen KoenigLawrence Scahill
Jan 21, 2015·Current Opinion in Psychiatry·Na Young Ji, Robert L Findling
Nov 21, 2019·Aging·Sabah NisarMohammad Haris
Jul 8, 2020·International Journal of Molecular Sciences·Ann Genovese, Merlin G Butler
Sep 15, 2015·Clinical Neuropharmacology·Roberto Canitano
Dec 12, 2019·Frontiers in Psychiatry·Sina HafiziMeng-Chuan Lai
Apr 25, 2020·Jornal de pediatria·Adriana Rocha BritoMarcio Moacyr Vasconcelos
Jan 27, 2021·Health and Quality of Life Outcomes·Gian Loreto D'AlòUNKNOWN ISACAGuideline Working Group
Apr 16, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Antonio M PersicoCelso Arango
Jun 24, 2021·Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater·Christian PopowPaul Plener
Sep 8, 2021·Journal of Autism and Developmental Disorders·Erin HenneberryCraig A Erickson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.